RTP On Demand: Current and Future Role of PARP Inhibitors in the Management of Ovarian Cancer (Video Program) - Video 21Investigational strategies with anti-PD-1 checkpoint inhibitors in OC
2:05 minutes.
TRANSCRIPTION:
DR LOVE: I thought I saw that you’re running a trial of a checkpoint inhibitor with a PARP inhibitor. DR MATULONIS: Yes. Our group is running — part of our Stand up to Cancer ovarian cancer team — Panos Konstantinopoulos is the PI of that study. And that’s a combination of pembrolizumab, PD-1 inhibitor, plus niraparib. DR LOVE: And are you using PD-1 levels? We were talking about the big lung thing in Copenhagen. Are these patients only PD-1-positive, or everybody? DR MATULONIS: It’s everybody, but it’s specifically patients who are platinum resistant but who have displayed prior sensitivity to platinum. So initially platinum sensitive but then platinum resistant. DR LOVE: You mentioned that the single-agent checkpoint inhibitors haven’t looked all that great. But what are the PD-1 levels that you see in ovarian cancer? DR MATULONIS: They are — it really depends upon the assay. I think ovarian cancer can be PD-L1-positive. But they don’t seem to necessarily be predictive of response, at least at this point. So in the smaller trials of pembro, nivolumab and avelumab — pembro was specifically in patients who had cancers PD-L1-positive, but the others were mixed. That’s where you see these between 10% to 15% response rates, all in heavily pretreated patients. We’re just finishing up the KEYNOTE-100 trial that looks at single-agent pembrolizumab, not based upon PD-L1. But PD-L1 is being looked at retrospectively to try to tease out what effect PD-L1 levels have, and also, does platinum resistance make a difference, platinum sensitive make a difference? How many prior lines? But I think that ovarian cancer is, I think, very potentially an immunogenic cancer, but it may need something in addition to a PD-1 or PD-L1 inhibitor. |